Results 191 to 200 of about 8,896 (223)

Intraoperative fluid restriction in hyperthermic intraperitoneal chemotherapy

Journal of Surgical Research, 2018
Multiple studies highlight the importance of liberal fluid administration in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Over-resuscitation can delay recovery and wound healing. We report an intraoperative protocol that restricts fluid administration and minimizes morbidity.Retrospective analysis of 35 patients ...
Tariq Almerey, Emmanuel M. Gabriel, Klaus D. Torp, Sanjay P. Bagaria   +3 more
openaire   +2 more sources

Hyperthermic Intraoperative Intraperitoneal Chemotherapy Safety Considerations

AORN Journal, 1996
ABSTRACTPerioperative staff members encounter many occupational exposure hazards in the workplace. Cytotoxic agent exposure is a relatively new hazard that perioperative staff members are experiencing as more surgeons use hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) to treat patients with abdominopelvic cavity malignancies. Routes of
S K, White, A D, Stephens, P H, Sugarbaker   +2 more
openaire   +2 more sources

The approval process for hyperthermic intraoperative intraperitoneal chemotherapy

European Journal of Surgical Oncology (EJSO), 2006
To clarify the requirements for Food and Drug Administration approval in the United States for hyperthermic intraoperative intraperitoneal chemotherapy administration. Also, to review the status of the approval process in Europe.The obstacles to be overcome for approval by the Food and Drug Administration for a new drug approval and for a new device ...
P H, Sugarbaker, L, Clarke
openaire   +2 more sources

Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy

Anaesthesia, 2009
Summary Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is used for selected gastrointestinal carcinomas. We report a case of ventricular tachycardia during HIPEC with cisplatin that persisted as long as the chemotherapy solution remained in the intra‐abdominal cavity.
C A, Thix, I, Königsrainer, R, Kind, P, Wied, T H, Schroeder   +4 more
openaire   +2 more sources

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

BJA Education, 2021
S, Durnford, L, Boss, J, Bell
openaire   +2 more sources

Adjuvant hyperthermic intraperitoneal chemotherapy for adenocarcinoma of the pancreas

1996
Each year in the United States, approximately 28,000 people develop cancer of the pancreas, resulting in an incidence of 9 cases per 100,000 population [1,2]. Although the incidence of cancers at several other sites is higher, pancreatic carcinoma is the fourth leading cause of cancer death behind malignancies of the lung, prostate, and colorectum in ...
S E, Ettinghausen, A M, Averbach
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy: An Overview #412

Journal of Palliative Medicine, 2021
Ryan, Morgan, Sandy, Tun, Oliver S, Eng
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy

Surgical Oncology Clinics of North America, 2012
Santiago González-Moreno, Luis González-Bayón, Gloria Ortega-Pérez   +2 more
openaire   +1 more source

Hyperthermic Intraperitoneal Chemotherapy

Journal of PeriAnesthesia Nursing
Alisar M, Aljundi, Rachel C, Wolfe
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer

Biomedical Journal, 2022
Kuan-Gen Huang, Yu-Bin Pan, Lan-Yan Yang   +2 more
exaly